<p>Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients</p>-Reference-Cited by-同舟云学术

Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients

Published:2020-10 Issue: Volume:Volume 12 Page:10091-10101
ISSN:1179-1322
Container-title:Cancer Management and Research
language:en
Short-container-title:CMAR

Author:

Yu Shan,Wang Yan,Cheng Xi^ORCID,Lv Minzhi,Cui Yuehong,Li Wei,Yu Yiyi^ORCID,Li Qian,Liu Tianshu^ORCID

Publisher

Informa UK Limited

Subject

Oncology

Reference28 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Cancer statistics, 2020

3. NCCN Clinlcal Practice Guidelines in Oncology (NCCN Guidelines). Gastric Cancer. Version 4.2019. Fort Washington: National Comprehensive Cancer Network; 2019.

4. Updates on esophageal and gastric cancers

5. The patterns and timing of recurrence after curative resection for gastric cancer in China

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of PI3K/Akt/mTOR Signaling Pathway Suppresses 5-Fluorouracil Resistance in Gastric Cancer;Molecular Biotechnology;2023-11-24

2. Prognostic Model of D2 Radical Gastrectomy Combined with Neoadjuvant Chemotherapy for Gastric Cancer;Risk Management and Healthcare Policy;2023-07

3. Real-World Study: A Powerful Tool for Malignant Tumor Research in General Surgery;Cancers;2022-11-02

4. Comparison of S-1-based vs. capecitabine-based adjuvant chemotherapy for patients with gastric cancer: a systematic review and meta-analysis;European Journal of Clinical Pharmacology;2021-07-17